<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00655512</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-OCT011-023</org_study_id>
    <nct_id>NCT00655512</nct_id>
  </id_info>
  <brief_title>Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound</brief_title>
  <acronym>OCT</acronym>
  <official_title>Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream (Elidel® 1% Cream), Hydrocortisonacetat 1% Cream (Hydrogalen® Cream), Betamethasonvalerat 0,1% Cream (Betagalen® Cream) and Clobetasol-17-propionat 0,05% Cream (Clobegalen® Cream) Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound - a Single Blind, Placebo-controlled, Randomized, Monocenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      to compare the atrophogenic potentials of pimecrolimus 1% cream, hydrocortisonacetat 1%
      cream, betamethasonvalerat 0,1% cream and clobetasol-17-Propionat 0,05% cream
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>thickness of epidermis</measure>
    <time_frame>9 times in 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>atrophogenic effect assessed by dermaphot</measure>
    <time_frame>9 times in 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>moisture of skin assessed by corneometer</measure>
    <time_frame>9 times in 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transpire of skin assessed by tewameter</measure>
    <time_frame>9 times in 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thickness of dermis</measure>
    <time_frame>9 times in 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pimecrolimus 1% cream</intervention_name>
    <description>twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Elidel 1% cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrocortisonacetat 1% cream</intervention_name>
    <description>twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Hydrogalen cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>betamethasonvalerat 0,1% cream</intervention_name>
    <description>twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Betagalen cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clobetasol-17-propionat 0,05% cream</intervention_name>
    <description>twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Clobegalen cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and female probands age between 18-40 years

          -  skin healthy

          -  skintype I-III according to Fitzpatrick

        Exclusion Criteria:

          -  women of childbearing potential without adequate contraception

          -  pregnant or breastfeeding

          -  genetic defect of epidermal barrier

          -  external or systemic treatment with drugs, which probably have an effect to the
             thickness of skin or to the production of teleangiektasien within the last 6 month
             before study entry

          -  skin disease, which hinder the evaluation with OCT, ultrasound or dermaphot

          -  UV treatment within the last 4 weeks before study entry

          -  participation to another clinical trial within the last 30 days before study entry

          -  allergy against pimecrolimus or hydrocortison or betamethasonvalerat or
             Clobetasol-17-propionat

          -  severe systemic diseases; ongoing immunosuppressive treatment

          -  planned vaccination should realize before study entry or 28 days after end of
             treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland Aschoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, Medical Faculty, Technical University Dresden, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology, Medical Faculty, TU Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2008</study_first_submitted>
  <study_first_submitted_qc>April 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2008</study_first_posted>
  <last_update_submitted>June 10, 2014</last_update_submitted>
  <last_update_submitted_qc>June 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pimecrolimus</keyword>
  <keyword>hydrocortison</keyword>
  <keyword>betamethasone</keyword>
  <keyword>clobetasol-17-Propionat</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <keyword>skin healthy probands</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimecrolimus</mesh_term>
    <mesh_term>Clobetasol</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

